<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780299</url>
  </required_header>
  <id_info>
    <org_study_id>P071005</org_study_id>
    <nct_id>NCT00780299</nct_id>
  </id_info>
  <brief_title>Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability in Post-resuscitation Shock</brief_title>
  <acronym>Hyperdia</acronym>
  <official_title>Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability (HDHP) During the Early Period of Post-resuscitation Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Industries, MEYZIEU, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Despite spontaneous cardiac activity recovery, a shock occurs in more than half of&#xD;
      patients after resuscitation for cardiac arrest. This acute circulatory insufficiency&#xD;
      presents similar characteristics with septic shock and is responsible of most early deaths.&#xD;
      Most frequently, usual treatments are unable to control this shock and to avoid the&#xD;
      appearance of multiple organ failure.&#xD;
&#xD;
      Aim of the study: In addition to conventional therapeutics, an early plasma epuration of&#xD;
      inflammatory mediators (HDHP) could be able to improve hemodynamic parameters and to reduce&#xD;
      the shock duration. This improvement could have an impact on multiple organ dysfunctions and&#xD;
      also on early mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HDHP (plasma epuration of inflammatory mediators) will be used in addition to the current&#xD;
      clinical practice. The experimental arm will be treated by HDHP device.&#xD;
&#xD;
      The high permeability membrane SepteX is a membrane polyarylethersulfone sold by Gambro that&#xD;
      allows the purification of molecules of average size to near 50 kd molecular weight.&#xD;
&#xD;
      We can thus purify molecules larger molecular weight than hemofiltration can with the usual&#xD;
      membranes (30 kd). Furthermore, this increase in permeability allows a significant treatment&#xD;
      medium-sized molecules in diffusion (hemodialysis), that the usual membranes do not allow.&#xD;
      Finally, it is possible to purify certain molecules that hemofiltration including high volume&#xD;
      does not allow (TNFalpha for example).&#xD;
&#xD;
      Use of this membrane requires the use of specific set dedicated machine Prismaflex itself&#xD;
      with a specific software (Exceed) to ensure the control and security of processing.&#xD;
&#xD;
      2 sessions of HDHP will be performed in the first 48 hours following ICU admission (with&#xD;
      inclusion in the first 8 hours).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2008</start_date>
  <completion_date type="Actual">January 2, 2016</completion_date>
  <primary_completion_date type="Actual">January 2, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main endpoint will be the duration of the shock expressed by the length of catecholamine infusion</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in organ dysfunction score (SOFA, LOD) during the first 7 days Mortality at day 7 and day 28 Incidence of side effects and complications due to HDHP Impact of HDHP on inflammatory parameters.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Sudden Cardiac Death</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDHP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemodialysis with high permeability (HDHP)</intervention_name>
    <description>HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CVVH</intervention_name>
    <description>hemofiltration intermittent dialysis</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Comatous patients admitted to the ICU for a sudden cardiac death apparently related to&#xD;
             heart disease and requiring catecholamine infusion to treat a shock&#xD;
&#xD;
          -  Cardiac arrest in front of witnesses&#xD;
&#xD;
          -  Written informed consent obtained from the family or by emergency procedure&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Response to verbal commands (Glasgow score &gt;7)&#xD;
&#xD;
          -  Terminal illness present before the cardiac arrest&#xD;
&#xD;
          -  Acquired or innate immune deficit&#xD;
&#xD;
          -  Anticoagulation not recommended or high hemorrhagic risk&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  weight &gt; 100 kg&#xD;
&#xD;
          -  without social security&#xD;
&#xD;
          -  another clinical trial ongoing&#xD;
&#xD;
          -  cardiac arrest from non cardiac etiology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Cariou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical intensive care unit of Cochin-St Vincent de Paul university Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Geri G, Grimaldi D, Seguin T, Lamhaut L, Marin N, Chiche JD, Pène F, Bouglé A, Daviaud F, Morichau-Beauchant T, Arnaout M, Champigneulle B, Zafrani L, Bourcier S, Nguyen YL, Charpentier J, Mira JP, Coste J, Vinsonneau C, Cariou A. Hemodynamic efficiency of hemodialysis treatment with high cut-off membrane during the early period of post-resuscitation shock: The HYPERDIA trial. Resuscitation. 2019 Jul;140:170-177. doi: 10.1016/j.resuscitation.2019.03.045. Epub 2019 Apr 8.</citation>
    <PMID>30974188</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasma epuration</keyword>
  <keyword>Hemofiltration</keyword>
  <keyword>Cardiac arrest</keyword>
  <keyword>Shock</keyword>
  <keyword>Inflammatory mediators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

